A big pharmaceutical corporation based in Western Europe with offices worldwide forms partnerships with early-stage biotech companies. The firm also invests via a venture arm, which is highly strategic in nature; the firm shares access to opportunities with the fund. The firm invests in technologies from an early discovery stage onwards, and partners with companies worldwide.

The firm’s therapeutic areas are Oncology & Cancer Immunotherapy, Ophthalmology, Immunology, Infectious Disease & Specialty Care, and Neuroscience. In the oncology sector, the firm seeks assets that have a biomarker hypothesis that can be used to select and stratify patient populations; in addition to therapeutic assets, biomarker diagnostics are also of interest. In Ophthalmology, the firm focuses on ‘back of the eye’ diseases such as AMD, diabetic retinopathy, and diabetic macular edema, and is also interested in other eye diseases such as retinitis of prematurity, retinitis pigmentosa, uveitis, dry eye, and glaucoma. In immunology/infectious disease, the firm focuses on hepatitis B, influenza and antibacterials; the firm is also interested in respiratory infections, HPV and HIV. In neurology, the firm focuses on neurodegenerative diseases (Alzheimer’s, Parkinson’s), schizophrenia, multiple sclerosis, depression, and autism spectrum disorders. Opportunities from the lead op stage onwards are evaluated by the firm’s therapeutic area groups.

The firm is interested in companies that align with the firm’s areas of focus and which have attained proof of principle or proof of concept data for their asset, and prefers that assets have obtained robust preclinical data across several species. Evidence of target engagement is of importance. In oncology assets, the possibility of combinability with the firm’s asset is also of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture-capital firm supports early stage companies in the Mid-Atlantic Region – Maryland, Virginia, Washington, DC, and North Carolina. The firm makes approximately 6 investments per year into companies seeking investment rounds less than $4m. During a single round, the firm will typically make an equity investment of $500k to $1.0m. For companies that require larger financing rounds, the firm will look to syndicate deals with other investment groups in their network.

The firm is interested in medical devices (class 1 or 2) and healthcare IT opportunities. The firm looks for companies already generating revenues or close, within 12-18 months of doing so. Within medical devices, the firm requires FDA clearance or close to doing so. The firm is open to all indication areas.

The firm looks for a strong, proven leadership team with a clear path and desire to exit, unique value proposition, competitive term sheet and interest in investors who can provide value beyond the checkbook.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A specialist healthcare company with offices in Europe, North America, and Australia, is looking to in-license and acquire therapeutics and medical devices that are of strategic interest. The firm is capable of making allocations ranging from £10 million to over £100 and more for later stage acquisitions. The firm is primarily interested in companies that are looking to be marketed in the United States although they are open to global opportunities as well.

The firm is interested in Therapeutic assets and Medical Devices. For therapeutics the firm’s current products include antidotes to treat snake envenomation and toxicity associated with medicines used for heart conditions and cancer. The firm is open to therapeutics within these areas as well as other indications pending they are intended to be hospital products. The firm primarily focuses on small molecule therapeutics. For medical devices the firm is looking for companies that have 510 K approval in Oncology, Vascular and Pulmonary fields. The firm’s current device products include Interventional Oncology products used to treat patients with liver tumors and Interventional Vascular products used to treat patients with severe blood clots.

The firm is interested in working with founding management teams prior to investment and is open to in-license from public and private clients.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in Birmingham, Alabama invests in a number of sectors, including healthcare, real estate, and finance. The firm typically makes co-investments between $100,000 and $3 million, and looks to make 5-6 investments within the next year. The firm is open to investments globally.

The firm is open to all sectors and subsectors of life science—biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm is agnostic in terms of indications and is open to all phases of development.

The firm requires companies to have a management team set in place, and will help fill the board, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A healthcare-focused, evergreen fund based in California is looking for new life science opportunities. The firm is mainly focused on therapeutics and will consider platform technologies, however only platforms capable of generating drug candidates. The firm’s investment size varies widely depending on the needs of the company, and will make investments of up to $5M. The capital structure depends on the financing round, with convertible notes being preferred for seed rounds and equity for everything else; no debt financing. The firm only co-invests, and does not lead rounds. The firm has some limitations on geographic exposure and will consider companies in any part of the U.S., Western Canada or England.

The firm invests in therapeutics that treat rare and ultra-rare/orphan diseases. The firm is interested in earlier stage assets and will consider anything from preclinical up unto phase IIa. In the past, the firm has invested in therapeutics, which treat unmet needs in glaucoma, patients with prosthetic heart valves and renal dysfunction as well as a small molecule to treat Alzheimer’s disease. The firm will consider early-stage therapeutics to treat orphan disease including small molecules, biologics, repurposed drugs or biosimilars, cell/gene therapy candidates (least interest) and platform technologies (that generate drug candidates). The firm is not interested in diagnostics, medical devices or healthcare IT.

The firm does not have any specific management team requirements, and will work with all entrepreneurs. A board seat is not always required, but is not uncommon.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global private equity firm based in California has over $50 billion AUM and invests across development stages, from early to late stages. The firm’s investment size is highly variable depending on the stage of the company, ranging from $1M to $25M in equity. The firm has a global mandate and is actively seeking new investment opportunities.

The firm seeks compelling investment opportunities in drug discovery and development platforms developing novel therapeutics, medical devices, healthcare services and healthcare IT. For therapeutics, the firm seeks small molecules and biologics and is open to all indications including orphan indications. The firm will consider products in all phases of clinical trials, from pre-clinical to phase III, and also commercial stage therapeutics. The firm is open to both PMA and 510K devices, as long as the device is already being sold at a commercial stage. The firm is also interested in services such as CROs and CMOs as well as tools of genomics and proteomics.

The firm invests for the long term, and is heavily involved in, and committed to, the growth and success of their portfolio companies. The firm therefore generally take a board seat/observer rights. The firm only invests in private companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A specialist healthcare company with offices worldwide is looking to in-license and acquire therapeutics and medical devices that are of strategic interest. The firm is capable of making allocations ranging from £10 million to over £100 and more for later stage acquisitions. The firm is primarily interested in companies that are looking to be marketed in the United States although they are open to global opportunities as well.

The firm is interested in Therapeutic assets and Medical Devices. For therapeutics the firm’s current products include antidotes to treat snake envenomation and toxicity associated with medicines used for heart conditions and cancer. The firm is open to therapeutics within these areas as well as other indications pending they are intended to be hospital products. The firm primarily focuses on small molecule therapeutics. For medical devices the firm is looking for companies that have 510 K approval in Oncology, Vascular and Pulmonary fields. The firm’s current device products include Interventional Oncology products used to treat patients with liver tumors and Interventional Vascular products used to treat patients with severe blood clots.

The firm is interested in working with founding management teams prior to investment and is open to in-licensing from public and private clients.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com